<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75725">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140944</url>
  </required_header>
  <id_info>
    <org_study_id>IMPAACT P1107</org_study_id>
    <secondary_id>UM1AI068632</secondary_id>
    <secondary_id>UM1AI068616</secondary_id>
    <secondary_id>UM1AI106716</secondary_id>
    <nct_id>NCT02140944</nct_id>
  </id_info>
  <brief_title>IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence</brief_title>
  <official_title>IMPAACT P1107: Cord Blood Transplantation With CCR5Δ32 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPAACT P1107 will describe the outcomes of HIV-infected persons, ages 12 months and older,
      who undergo transplantation with CCR5Δ32 cord blood stem cells for treatment of cancer,
      hematopoietic disease, or other underlying disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Through 5 years post-transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Survival and event-free survival at 100 days, Week 26, Week 52, and then every six months until five years post-transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft versus host disease</measure>
    <time_frame>Through 5 years post-transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Graft versus host disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment</measure>
    <time_frame>Through 5 years post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Chimerism (≥ 98% of blood cells bearing CCR5∆32) and time to hematopoietic cell and immune recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV DNA level</measure>
    <time_frame>Through 5 years post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>HIV-1 proviral DNA levels in peripheral blood</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Pre-Transplant Cohort</arm_group_label>
    <description>HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Transplant Cohort</arm_group_label>
    <description>HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For consenting participants, blood and tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1 infected children and adults who undergo cord blood stem cell transplantation for
        treatment of cancer, hematopoietic disease, or other underlying disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV-1 infection

          -  12 months of age or older

          -  Willing to provide written informed consent

          -  Pre-Transplant Cohort: Underlying disease appropriate for stem cell transplant, as
             determined by the transplant team as part of standard of care.

          -  Pre-Transplant Cohort: Availability of an appropriately matched (as determined by the
             transplant center) CCR5Δ32 cord blood unit (homozygous or heterozygous) and intention
             to proceed with transplantation. NOTE:  Double cord transplants are allowed.  If a
             double cord is used, at least one cord blood unit should be CCR5∆32 (homozygous or
             heterozygous).

          -  Pre-Transplant Cohort:  Received a CCR5Δ32 homozygous cord blood or bone marrow
             transplant within the last two years.

        Exclusion Criteria:

        • Received, or planning to receive, more than one CCR5Δ32 homozygous cord blood or bone
        marrow transplant.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Bryson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Coletti, MS</last_name>
    <phone>919-544-7040</phone>
    <phone_ext>11238</phone_ext>
    <email>acoletti@fhi360.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachel Presti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.impaactnetwork.org/studies/P1107.asp</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord blood transplantation</keyword>
  <keyword>CCR5Δ32</keyword>
  <keyword>HIV cure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
